Veeva Systems is a cloud-based software company focused on the healthcare sector. It provides solutions for life sciences companies, including customer relationship management, content management, and data analytics. Major business segments include Veeva Vault, Veeva CRM, and Veeva Network, which cater to various operational needs in clinical, regulatory, and commercial functions. The primary revenue source is subscription fees from its software products and services.
The investment profile of Veeva Systems is more aligned with growth investors, given its focus on expanding its software solutions in the healthcare market. The company has shown moderate revenue growth, but recent earnings surprises indicate potential volatility. This profile may appeal to those looking for long-term capital appreciation rather than immediate income.
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-07-25 | Hold | Buy | Solid fundamentals, but mixed momentum signals present uncertainty. |
| 2026-07-23 | Buy | Hold | Mixed momentum; fundamentals show some strength. |
| 2026-07-08 | Hold | Buy | Strong growth but mixed momentum signals present risks. |
| 2026-07-01 | Sell | Hold | Positive momentum but mixed fundamentals warrant caution. |
| 2026-06-09 | Hold | Sell | Weak fundamentals and negative momentum raise significant concerns. |
| 2026-06-01 | Sell | Hold | Recent gains offset by negative long-term momentum. |
| 2026-05-08 | — | Sell | Weak momentum and high risk; cautious approach advised. |
| 2026-05-08 | Sell | Sell | Компания Veeva Systems демонстрирует умеренный рост выручки, но значительное падение акций за последние месяцы указывает на высокие риски. Рекомендуется удерживать позицию до более ясных сигналов о восстановлении. |
| 2026-04-19 | Hold | Sell | Компания Veeva Systems демонстрирует смешанные результаты, с недавним падением цен на акции и негативным сюрпризом по прибыли. Учитывая текущие риски и неопределенности, рекомендуется удерживать акции. |
| 2026-04-11 | Sell | Hold | Компания Veeva Systems демонстрирует значительное снижение котировок за последние месяцы, что указывает на высокие риски. Учитывая негативные финансовые показатели и снижение прибыли, рекомендуется продавать акции. |
| 2026-03-22 | Hold | Sell | Компания демонстрирует положительный рост выручки и EPS, однако значительное снижение цен за последние 120 дней и высокая волатильность указывают на риски. Рекомендуется удерживать акции до более ясных сигналов о восстан |
| 2026-03-06 | — | Hold | Компания Veeva Systems демонстрирует значительное снижение на длительном горизонте, однако недавний рост может указывать на краткосрочную коррекцию. Рекомендуется удерживать акции до более ясных сигналов о восстановлении |
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-09-08 | Wells Fargo | Target Raised | — → 330 | 275.09 |
| 2026-08-27 | Truist Financial | Target Raised | 262 → 305 | 288.01 |
| 2026-08-27 | Raymond James | Target Raised | 225 → 330 | 295.78 |
| 2026-08-27 | UBS | Target Raised | 275 → 325 | 294.74 |
| 2026-08-27 | RBC Capital | Target Raised | — → 325 | 286.68 |
| 2026-08-27 | Evercore ISI | Target Raised | 185 → 250 | 244.69 |
| 2026-08-27 | Piper Sandler | Target Raised | — → 320 | 286.465 |
| 2026-08-27 | Stifel Nicolaus | Target Raised | — → 300 | 294.45511 |
| 2026-08-27 | Morgan Stanley | Target Raised | 215 → 275 | 244.69 |
| 2026-08-27 | BMO Capital | Target Raised | 175 → 270 | 244.69 |
| 2026-08-27 | Mizuho Securities | Target Raised | 270 → 280 | 244.69 |
| 2026-08-24 | Needham | Update | — → 270 | 247.9 |
| 2026-08-24 | Piper Sandler | Update | — → 295 | 247.9 |
| 2026-08-20 | Guggenheim | Target Raised | — → 276 | 251 |
| 2026-08-18 | Barclays | Target Raised | 235 → 275 | 238.34 |
| 2026-08-17 | Oppenheimer | Target Raised | 225 → 300 | 243.75 |
| 2026-08-17 | Stifel Nicolaus | Target Raised | 230 → 275 | 243.75 |
| 2026-07-22 | Guggenheim | Update | — → 232 | 184.55 |
| 2026-06-04 | BNP Paribas | Target Lowered | — → 285 | 178.66 |
| 2026-06-04 | Morgan Stanley | Update | — → 215 | 178.66 |
| 2026-06-04 | BMO Capital | Target Lowered | 220 → 175 | 178.66 |
| 2026-06-04 | Robert W. Baird | Target Raised | 250 → 260 | 178.66 |
| 2026-06-04 | Canaccord Genuity | Target Lowered | 235 → 220 | 178.66 |
| 2026-06-04 | Mizuho Securities | Target Lowered | — → 270 | 178.66 |
| 2026-06-04 | Goldman Sachs | Target Lowered | 190 → 165 | 178.66 |
| 2026-06-04 | Wells Fargo | Target Raised | — → 320 | 178.66 |
| 2026-06-04 | UBS | Target Lowered | 250 → 235 | 178.66 |
| 2026-06-04 | Evercore ISI | Target Lowered | — → 185 | 178.66 |
| 2026-02-24 | Oppenheimer | Target Lowered | 325 → 275 | 172.17 |
| 2026-02-17 | Morgan Stanley | Rating Upgraded | — → 205 | 174.11 |
| 2026-02-04 | Mizuho Securities | Target Lowered | 325 → 295 | 190.8 |
| 2026-01-13 | Goldman Sachs | Update | — → 215 | 233.21 |
| 2026-01-08 | Robert W. Baird | Target Lowered | 319 → 283 | 243.69 |
| 2025-12-04 | Morgan Stanley | Update | — → 222 | 244.22 |
| 2025-11-25 | Wells Fargo | Target Lowered | 341 → 333 | 235.74 |
| 2025-11-24 | Jefferies | Target Lowered | — → 330 | 244.06 |
| 2025-11-21 | Robert W. Baird | Target Raised | 314 → 319 | 270.5 |
| 2025-11-21 | UBS | Target Lowered | 310 → 280 | 270.5 |
